| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Madhavi Maddali, Uday Prakash Kulkarni, Niveditha Ravindra, Arun Kumar Arunachalam, Arvind Venkatraman, Sharon Lionel, Marie Therese Manipadam, Anup J Devasia, Anu Korula, N A Fouzia, Aby Abraham, Alok Srivastava, Biju George, Poonkuzhali Balasubramanian, Vikram Mathew. Mutation profile in BCR-ABL1-negative myeloproliferative neoplasms: A single-center experience from India. Hematology/oncology and stem cell therapy. 2021-09-11. PMID:33789164. |
recurrent somatic mutations in the jak2, calreticulin (calr), and the mpl genes are described as drivers of bcr-abl1-negative myeloproliferative neoplasms (mpn) that includes polycythemia vera (pv), essential thrombocytosis (et), primary myelofibrosis (pmf), and mpn unclassified (mpn-u). |
2021-09-11 |
2023-08-13 |
Not clear |
| Soji Morishit. [Clinical impact of gene mutations on myeloproliferative neoplasms in Japan]. [Rinsho ketsueki] The Japanese journal of clinical hematology. vol 62. issue 8. 2021-09-10. PMID:34497192. |
jak2, calr, and mpl mutations are well-known driver mutations of mpn and are widely applied as diagnostic markers of mpn. |
2021-09-10 |
2023-08-13 |
Not clear |
| Razan Hayati Zulkeflee, Zefarina Zulkafli, Muhammad Farid Johan, Azlan Husin, Md Asiful Islam, Rosline Hassa. Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN). International journal of environmental research and public health. vol 18. issue 14. 2021-08-04. PMID:34300032. |
clinical and laboratory features of jak2 v617f, calr, and mpl mutations in malaysian patients with classical myeloproliferative neoplasm (mpn). |
2021-08-04 |
2023-08-13 |
Not clear |
| Razan Hayati Zulkeflee, Zefarina Zulkafli, Muhammad Farid Johan, Azlan Husin, Md Asiful Islam, Rosline Hassa. Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN). International journal of environmental research and public health. vol 18. issue 14. 2021-08-04. PMID:34300032. |
mutations of jak2v617f, calr, and mpl genes confirm the diagnosis of myeloproliferative neoplasm (mpn). |
2021-08-04 |
2023-08-13 |
Not clear |
| Razan Hayati Zulkeflee, Zefarina Zulkafli, Muhammad Farid Johan, Azlan Husin, Md Asiful Islam, Rosline Hassa. Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN). International journal of environmental research and public health. vol 18. issue 14. 2021-08-04. PMID:34300032. |
this study aims to determine the genetic profile of jak2v617f, calr exon 9 type 1 (52 bp deletion) and type 2 (5 bp insertion), and mpl w515 l/k genes among malaysian patients and correlate these mutations with clinical and hematologic parameters in mpn. |
2021-08-04 |
2023-08-13 |
Not clear |
| Mi-Ae Jang, Chul Won Cho. Recent insights regarding the molecular basis of myeloproliferative neoplasms. The Korean journal of internal medicine. vol 35. issue 1. 2021-06-24. PMID:31778606. |
mpn driver mutations in genes associated with the jak-stat pathway include jak2 v617f, jak2 exon 12 mutations and mutations in mpl, calr, and csf3r. |
2021-06-24 |
2023-08-13 |
Not clear |
| Sarada Achyutuni, Harini Nivarthi, Andrea Majoros, Eva Hug, Christina Schueller, Ruochen Jia, Cecilia Varga, Michael Schuster, Martin Senekowitsch, Dimitris Tsiantoulas, Anoop Kavirayani, Christoph J Binder, Christoph Bock, Oleh Zagrijtschuk, Robert Kralovic. Hematopoietic expression of a chimeric murine-human CALR oncoprotein allows the assessment of anti-CALR antibody immunotherapies in vivo. American journal of hematology. vol 96. issue 6. 2021-06-24. PMID:33761144. |
mutations in jak2, calr and mpl genes are known to be three prominent mpn disease drivers. |
2021-06-24 |
2023-08-13 |
mouse |
| Sarada Achyutuni, Harini Nivarthi, Andrea Majoros, Eva Hug, Christina Schueller, Ruochen Jia, Cecilia Varga, Michael Schuster, Martin Senekowitsch, Dimitris Tsiantoulas, Anoop Kavirayani, Christoph J Binder, Christoph Bock, Oleh Zagrijtschuk, Robert Kralovic. Hematopoietic expression of a chimeric murine-human CALR oncoprotein allows the assessment of anti-CALR antibody immunotherapies in vivo. American journal of hematology. vol 96. issue 6. 2021-06-24. PMID:33761144. |
mutant calr (mutcalr) is an oncoprotein that interacts with and activates the thrombopoietin receptor (mpl) and represents an attractive target for targeted therapy of calr mutated mpn. |
2021-06-24 |
2023-08-13 |
mouse |
| Yuka Sugimoto, Keiki Nagaharu, Kohshi Ohishi, Maki Nakamura, Makoto Ikejiri, Kaname Nakatani, Minoru Mizutani, Shigehisa Tamaki, Takeshi Ikeda, Isao Tawara, Naoyuki Katayam. MPL exon 10 mutations other than canonical MPL W515L/K mutations identified by in-house MPL exon 10 direct sequencing in essential thrombocythemia. International journal of hematology. vol 113. issue 5. 2021-06-07. PMID:33770389. |
since 2009, mpl exon 10 mutation analysis has been performed for diagnosis of myeloproliferative neoplasms (mpn) without jak2 v617f or calr exon 9 mutations. |
2021-06-07 |
2023-08-13 |
Not clear |
| Yuka Sugimoto, Keiki Nagaharu, Kohshi Ohishi, Maki Nakamura, Makoto Ikejiri, Kaname Nakatani, Minoru Mizutani, Shigehisa Tamaki, Takeshi Ikeda, Isao Tawara, Naoyuki Katayam. MPL exon 10 mutations other than canonical MPL W515L/K mutations identified by in-house MPL exon 10 direct sequencing in essential thrombocythemia. International journal of hematology. vol 113. issue 5. 2021-06-07. PMID:33770389. |
so far, 11 cases of mpl exon 10 mutation have been found in 51 patients with suspected mpn. |
2021-06-07 |
2023-08-13 |
Not clear |
| Yuka Sugimoto, Keiki Nagaharu, Kohshi Ohishi, Maki Nakamura, Makoto Ikejiri, Kaname Nakatani, Minoru Mizutani, Shigehisa Tamaki, Takeshi Ikeda, Isao Tawara, Naoyuki Katayam. MPL exon 10 mutations other than canonical MPL W515L/K mutations identified by in-house MPL exon 10 direct sequencing in essential thrombocythemia. International journal of hematology. vol 113. issue 5. 2021-06-07. PMID:33770389. |
further cases need to be examined to elucidate the full mpl mutation profile in mpn. |
2021-06-07 |
2023-08-13 |
Not clear |
| Jeanne F Rivera, April J Baral, Fatima Nadat, Grace Boyd, Rachael Smyth, Hershna Patel, Emma L Burman, Ghadah Alameer, Sally A Boxall, Brian R Jackson, E Joanna Baxter, Peter Laslo, Anthony R Green, David G Kent, Ann Mullally, Edwin Che. Zinc-dependent multimerization of mutant calreticulin is required for MPL binding and MPN pathogenesis. Blood advances. vol 5. issue 7. 2021-05-31. PMID:33821991. |
zinc-dependent multimerization of mutant calreticulin is required for mpl binding and mpn pathogenesis. |
2021-05-31 |
2023-08-13 |
Not clear |
| Jerry L Spivak, Alison R Molitern. The Thrombopoietin Receptor, MPL, Is a Therapeutic Target of Opportunity in the MPN. Frontiers in oncology. vol 11. 2021-03-30. PMID:33777803. |
the thrombopoietin receptor, mpl, is a therapeutic target of opportunity in the mpn. |
2021-03-30 |
2023-08-13 |
Not clear |
| S Bartels, M Faisal, G Büsche, J Schlue, B Hasemeier, E Schipper, J Vogtmann, L Westphal, U Lehmann, H Kreip. [Bone marrow fibrosis in primary myelofibrosis in relation to myelodysplasia- and age-related mutations of hematopoietic cells]. Der Pathologe. vol 41. issue Suppl 2. 2021-01-27. PMID:33113046. |
age-related clonal hematopoiesis (arch) or clonal hematopoiesis of indetermined potential (chip) are frequent findings in the elderly and combinations with mpn driver mutations (jak2, mpl, and calr) have been described. |
2021-01-27 |
2023-08-13 |
Not clear |
| Ayalew Teffer. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. American journal of hematology. vol 96. issue 1. 2021-01-25. PMID:33197049. |
primary myelofibrosis (pmf) is a myeloproliferative neoplasm (mpn) characterized by stem cell-derived clonal myeloproliferation that is often but not always accompanied by jak2, calr, or mpl mutations. |
2021-01-25 |
2023-08-13 |
Not clear |
| Joe Lee, Anna L Godfrey, Jyoti Nangali. Genomic heterogeneity in myeloproliferative neoplasms and applications to clinical practice. Blood reviews. vol 42. 2021-01-19. PMID:32571583. |
the myeloproliferative neoplasms (mpn) polycythaemia vera, essential thrombocythaemia and primary myelofibrosis are chronic myeloid disorders associated most often with mutations in jak2, mpl and calr, and in some patients with additional acquired genomic lesions. |
2021-01-19 |
2023-08-13 |
Not clear |
| Yoko Edahiro, Marito Araki, Norio Komats. Mechanism underlying the development of myeloproliferative neoplasms through mutant calreticulin. Cancer science. vol 111. issue 8. 2020-12-07. PMID:32462673. |
studies have defined mutant calr as an oncogene promoting the development of mpn, and deciphered a novel molecular mechanism by which mutant calr constitutively activates thrombopoietin receptor mpl and its downstream molecules to induce cellular transformation. |
2020-12-07 |
2023-08-13 |
Not clear |
| Jan Jacques Michiels, Mihaela Tevet, Adrian Trifa, Emilia Niculescu-Mizil, Anca Lupu, Ana Maria Vladareanu, Horia Bumbea, Anca Ilea, Camelia Dobrea, Daniela Georgescu, Oana Patrinoiu, Mihaela Popescu, Meilin Murat, Cornel Dragan, Felicia Mihai, Sabina Zurac, Silvana Angelescu, Anamaria Iova, Alina Popa, Rodica Gogulescu, Violeta Popo. 2016 WHO Clinical Molecular and Pathological Criteria for Classification and Staging of Myeloproliferative Neoplasms (MPN) Caused by MPN Driver Mutations in the JAK2, MPL and CALR Genes in the Context of New 2016 WHO Classification: Prognostic and Therapeutic Implications. Maedica. vol 11. issue 1. 2020-10-01. PMID:28465746. |
2016 who clinical molecular and pathological criteria for classification and staging of myeloproliferative neoplasms (mpn) caused by mpn driver mutations in the jak2, mpl and calr genes in the context of new 2016 who classification: prognostic and therapeutic implications. |
2020-10-01 |
2023-08-13 |
Not clear |
| Irene Dogliotti, Carmen Fava, Anna Serra, Enrico Gottardi, Filomena Daraio, Francesca Carnuccio, Emilia Giugliano, Monica Bocchia, Giuseppe Saglio, Giovanna Rege-Cambri. CALR-positive myeloproliferative disorder in a patient with Ph-positive chronic myeloid leukemia in durable treatment-free remission: a case report. Stem cell investigation. vol 4. 2020-10-01. PMID:28725653. |
current diagnostic criteria for philadelphia-negative myeloproliferative neoplasia (mpn) have been redefined by the discovery of janus kinase 2 (jak2), myeloproliferative leukemia (mpl) and calreticulin (calr) genetic alterations. |
2020-10-01 |
2023-08-13 |
Not clear |
| Boguslaw A Kwiatkowski, Nicolas R Burwick, Robert E Richar. DLGAP1 directs megakaryocytic growth and differentiation in an MPL dependent manner in hematopoietic cells. Biomarker research. vol 7. 2020-10-01. PMID:31321035. |
aberrant mpl and downstream jak/stat signaling results in the development of the myeloproliferative neoplasms (mpn). |
2020-10-01 |
2023-08-13 |
Not clear |